GSK will acquire BELLUS Health for $14.75 per share in cash representing a total equity value of ~$2.0B at a premium of ~103% to BELLUS’ closing stock price. The transaction is expected to close in Q3’23
The acquisition gives GSK access to camlipixant (highly selective P2X3 antagonist) for adult patients with RCC. The acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant
Camlipixant is currently in P-III clinical development with anticipated regulatory approval & launch in 2026. In the P-IIb trial (SOOTHE) trial, camlipixant was shown to be effective at reducing 24hr. cough frequency with BID, 50 & 200mg oral dosing & 34% reduction in the rate vs PBO at 28 Day
Ref: GSK | Image: GSK
Related News:- GSK Entered into an Exclusive Licence Agreement and SCYNEXIS to Develop and Commercialise Brexafemme (ibrexafungerp) for Fungal Infection
